Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
Description:
Host: Jorge E. Cortes, MD
Although the first-generation tyrosine kinase inhibitors (TKIs) revolutionized the treatment of Ph+ CML-CP, the rate of resistance to these agents is high, and many patients require further treatment with second- and third-line therapy. The development of newer drugs with unique mechanisms that can overcome these resistance phenotypes offers new treatment strategies that can maintain response rates. This activity reviews the current treatment options for newly diagnosed disease and the importance of integrating patient preference when planning therapeutic regimens.